Yanqin Huang, MD, PhD

Yanqin joined the laboratory In January 2022 after after perfecting analysis in two compartment models in the Laboratory of Zachery P. Bulman at the University of Illinois.  In previous ventures, she was instrumental in the development of the MRX-1, also known as Contezalid, a new oxazalidinone antibiotic with reduced bone marrow toxicity compared to other approved oxazalidinone antibiotics such as linezolid,  and brings antimicrobial development experience from both academic and industry, including significant experience with the hollow fiber PK/PD models.  She is leading our nontuberculous mycobacterium efforts.